Drug intelligence / Profile preview

mRNA-1011

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

mRNA-1011 refers to a group of investigational mRNA-based seasonal influenza vaccine candidates developed by Moderna. These next-generation vaccines are designed to prevent seasonal influenza in adults aged 50 to 75 years by instructing the body's cells to produce specific viral proteins, primarily hemagglutinins, which then elicit a protective immune response against various influenza A and B strains. Specific candidates within this program, such as mRNA-1011.1 and mRNA-1011.2, aim to broaden coverage against multiple influenza A/H3N2 strains.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on mRNA-1011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1011.

Explore the full profile